Two of the three BRCA2 VUSs (D1923V and D1923A), were predicted to abolish the CK2 kinase binding at Ser1923 which is a highly evolutionarily conserved residue, also making these variants valid targets for functional analyses in breast cancer. Here, BRCA2 is linked to breast carcinoma.